Liver Blood Articles & Analysis
12 news found
Other less frequent adverse reactions reported with AMVUTTRA were dyspnea (shortness of breath), injection site reaction and an increase in blood alkaline phosphatase (a liver enzyme). Vutrisiran was previously granted Orphan Drug Designation in the European Union (EU) and U.S. for the treatment of ATTR amyloidosis and in Japan for transthyretin type familial ...
” Patients with Fontan circulation suffer from many associated end-organ dysfunctions caused by poor blood circulation like liver failure (Fontan-associated-liver-disease (FALD)), severe problems of the gut with uncontrollable diarrhoea (protein losing enteropathy) or life threatening lung affections (plastic bronchitis). ...
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. ...
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. ...
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction ...
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction ...
In this study the efficacy of rH225 was tested by assessing: the delayed mortality upon Jeko-1 MCL cell injection and the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver rH225 delayed significantly the body weight loss and the onset of clinical disease signs in mice inoculated with Jeko-1 MCL cells. ...
ByAbologix
In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population ...
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and ...
Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce ...
Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and ...
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS. Elevated levels of limonene in patients have been found to be indicative of a diseased liver. ...